June 30, 2009   United Kingdom

Diamyd has started a Phase II trial to examine whether the company's experimental vaccine, its lead candidate, which is also called Diamyd, is effective as a prophylactic treatment for children at high risk of developing diabetes.

Click here to read the article

Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.